InfantRisk Center

03/02/2026

📣 New Article Alert!
Curious about tirzepatide and breastfeeding? 🤱 Our latest article breaks down what the current evidence says about tirzepatide transfer into breast milk.

👉 Read more here: https://infantrisk.com/content/what-breastfeeding-moms-need-know-about-tirzepatide

Whether you’re considering tirzepatide for diabetes, weight management, or metabolic health while breastfeeding, get evidence-based guidance to help you make informed decisions with your healthcare provider. 💛

02/20/2026

We are incredibly honored to share that the InfantRisk Center has received the 2026 University Team Award for bringing distinction to the Texas Tech University Health Sciences Center through excellence in teaching, research, and service.

At InfantRisk, our mission is simple but powerful: to provide evidence-based information on the safety of medications during pregnancy and breastfeeding so that mothers, babies, and healthcare providers can make informed decisions with confidence. Through groundbreaking research, provider education, and direct support to families, our team works every day to close critical knowledge gaps in maternal and infant health.

This award reflects not only the scientific rigor behind our work, but also the heart behind our mission. We are deeply committed to serving women and families during some of the most vulnerable and important moments of their lives.

We are proud, grateful, and inspired to continue advancing research, education, and compassionate service. Thank you to TTUHSC for this distinguished recognition and to our incredible team who make this mission possible every single day.

02/09/2026

Tomorrow! ⏰
Join Dr. Kaytlin Krutsch for a live Q&A with Springer at 12:00 PM ET.
Bring your questions and jump into the conversation 👇
👉 Register here: https://bit.ly/4a7XTTL

01/27/2026

📢 New Case Report Published 📢

We’ve published a new case highlighting an important and rarely discussed issue in lactation care: the use of ethiodized oil during interventional radiology procedures.

🧠 Key takeaway:
Ethiodized oil contains an extremely high iodine load and is cleared slowly from the body. In this first reported case involving a lactating patient, iodine levels in breast milk remained 50–100× higher than normal more than a week after exposure, raising concerns for infant thyroid suppression. Care required breastfeeding interruption, milk testing, and close multidisciplinary planning.

💡 Why this matters:
Iodine actively concentrates in breast milk, and excessive exposure can impact infant thyroid function. Lactating patients need anticipatory guidance, thoughtful dosing, and coordinated care when agents like ethiodized oil are considered.

🔗 Read the article:
https://www.researchgate.net/publication/398801943_Periprocedural_Lactation_Considerations_After_Use_of_Ethiodized_Oil_in_an_Interventional_Radiology_Patient_A_Case_Report

📖 About access:
We wish this article could be open access, but publication fees are often ~$4,000 per paper. We’re working to steward limited resources in ways that create the greatest impact for patients, families, and clinicians, while continuing to generate and share high-value lactation research.

12/11/2025

Our founder, Dr. Tom Hale, stopped by for a visit this week! He even checked the oil on the LCMS 😂 — always keeping us on our toes.

We’re so grateful for his continued support and the legacy he’s built here. Happy to have him visit, and wishing everyone a warm and joyful holiday season! ❄️✨

12/11/2025

Our founder, Dr. Tom Hale, stopped by for a visit this week! He even checked the oil on the LC-MS 😂 — always keeping us on our toes.

We’re so grateful for his continued support and the legacy he’s built here. Happy to have him visit, and wishing everyone a warm and joyful holiday season! ❄️✨

12/04/2025

Cough and cold season is in full swing! 🤧
Do you know which cough and cold medicines are actually safe while breastfeeding?
We’re breaking down the options so you know what works and what keeps baby safe.

Info straight from experts for breastfeeding-safe options to treat a cold: cough, congestion, fever, allergies...and more. Plus, a chart of combo products!

12/02/2025

✨ New Journal Publication! ✨

Huge news for breastfeeding mothers with ADHD — our study on atomoxetine is published!

Our study shows that only very small amounts of atomoxetine enter breast milk. Most mothers had an RID under 0.2%, and even the highest level found was only 0.65%, suggesting very low risk while breastfeeding.

Because of this new evidence, we are updating atomoxetine’s lactation safety rating from L4 to L2, reflecting a much safer profile than previously thought.

A few reports of infant fussiness have been noted, so monitoring is still important. Any concerns should be reported to systems like FAERS to help strengthen safety data.

This research provides encouraging evidence that atomoxetine may be a safe, viable ADHD treatment for breastfeeding mothers.

https://journals.lww.com/psychopharmacology/fulltext/9900/atomoxetine_as_a_viable_adhd_treatment_in.482.aspx #:~:text=Conclusions:,of%20ADHD%20in%20lactating%20women.

11/19/2025

New Resource Alert!

Our full PRP and Breastfeeding Safety Guide is now live on our website.
If you’ve been curious about whether platelet-rich plasma (PRP) treatments are safe while nursing, we break down the science, safety data, and what to expect.

Read the full article here: https://infantrisk.com/content/platelet-rich-plasma-prp-treatments-and-breastfeeding

11/18/2025

Celebrating Excellence at the InfantRisk Center!

We are thrilled to recognize Emily Yamada, P2 pharmacy student in Amarillo, whose outstanding research represents not only her hard work but the continued scientific impact of the InfantRisk Center team.

Emily presented the poster, “Pharmacokinetic Analysis of Atomoxetine Transfer into Human Milk,” at the 2025 ILCA Annual Conference, where it was recognized for its exceptional scientific rigor. This project—developed through nearly a year of collaboration, mentorship, and teamwork at the InfantRisk Center—demonstrates the powerful research being done to improve medication safety for breastfeeding families.

We’re proud to share that the study’s manuscript has been accepted for publication in the Journal of Clinical Psychopharmacology (in press!), marking another milestone for both Emily and the InfantRisk Center’s research program.

Please join us in celebrating Emily’s achievement and the collective dedication of the InfantRisk Center team as we continue advancing evidence-based care for mothers and infants worldwide.

11/12/2025

Levi Campbell, PharmD, assistant professor of pharmacy practice, recently had original research, titled “Balancing mental health and breastfeeding: evaluating the transfer of lurasidone into human milk,” published in the Journal of Clinical Psychiatry. Congratulations, Dr. Campbell!
Learn more at: 🔗https://doi.org/10.4088/JCP.25m15955

11/03/2025

New Publication Alert!

We’re excited to announce our latest article: “Balancing Mental Health and Breastfeeding: Evaluating the Transfer of Lurasidone into Human Milk” published in the The Journal of Clinical Psychiatry by Levi S. Campbell, PharmD; Palika Datta, PhD; Kaytlin Krutsch, PhD, PharmD, MBA.

🔍 Why it matters:
• First-ever quantitative data on how the antipsychotic Lurasidone transfers into breast milk.
• Relative infant dose (RID) found to be only ~1.16% at the standard 40 mg/day maternal dose — well below the 10 % safety threshold.
• No adverse effects reported in exposed infants in the study sample.

Check out our study here:
https://www.psychiatrist.com/jcp/mental-health-breastfeeding-transfer-of-lurasidone-human-milk/